[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share; Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XI’AN, CHINA – August 17, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2010 Highlights · Revenue increases]
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share; Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XI’AN, CHINA – August 17, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2010 Highlights · Revenue increases]
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue Fromntinuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share;mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XIAN, CHINA August 17, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]
[Sinovac Reports Unaudited Second Quarter 2010 Financial Results - Conference call scheduled for Monday, August 16, 2010 at 8:00 AM EDT Beijing August 16, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading China-based vaccine manufacturer , announced today its un audited financial results for the three-month and six-month periods ended June 30, 2010. Financial Highlights ·] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Sinovac Reports Unaudited Second Quarter 2010 Financial Results - Conference call scheduled for Monday, August 16, 2010 at 8:00 AM EDT Beijing August 16, 2010 Sinovac Biotech Ltd. ( NASDAQ: SVA), a leading China-based vaccine manufacturer , announced today its un audited financial results for the three-month and six-month periods ended June 30, 2010. Financial Highlights ·] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]
[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue Fromntinuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share;mpany reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XIAN, CHINA August 17, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION 4] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Michael H. Lan, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v194087_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v194087_ex32-2.htm]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number 3 PART I.FINANCIAL INFORMATION 4 Item 1. Financial Statements 4nsolidated Balance Sheets of June 30, 2010 (unaudited) and December 31, 2009 4nsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months and Six Months Ended June 30, 2010 and 2009 (unaudited)] [CERTIFICATION I, Weibing Lu, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Michael H. Lan, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v194087_ex32-1.htm 5 EX-32.1] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) v194087_ex32-2.htm 6 EX-32.2]
